A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)

NCT02491268 | Completed Phase 2 DMC

• 1 other identifier: TRINEU1321
• Study Type: interventional
• Target: 166
• Locations: 1 country
• Sites: 1

Brief Summary

Epidemiological, clinicopathological and animal studies show that vascular disease in various forms contributes to cognitive decline. Increasing age is the strongest risk for dementia irrespective of whether it results from a vascular etiology or neurodegenerative disease processes such as in Alzheimer's disease (AD). AD and vascular cognitive impairment, the two most common causes of dementia, represent two extremes of a spectrum of disorders; however, a number of entities, which possess varying degrees of neurodegenerative and vascular pathologies, occur in between. The pure forms of the disorders are preferred for convenience to label, treat or manage but conditions within the spectrum are the norm rather than the exception as dementia advances. Therefore, combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia is a promising approach for the treatment of dementia in the elderly. Cilostazol acts as an antiplatelet agent and has other pleiotropic effects based on phosphodiesterase-3-dependent mechanisms. Increasing evidence suggests that cilostazol offers endothelial protection, via pleiotropic effects. Intriguingly, cilostazol has been shown to decrease amyloid beta (Abeta) accumulation and protect Abeta-induced cognitive deficits in an experimental model. In a pilot study of 10 patients with moderate AD (mean MMSE score, 11.9 points) who received donepezil, cilostazol add-on treatment for 5-6 months demonstrated significantly increased MMSE score in comparison to baseline. Moreover, cilostazol was shown to be effective in preventing cognitive decline in patients with AD with cerebrovascular diseases, mild cognitive impairment (MCI), and mild dementia who received donepezil. These results highlight the need for a comprehensive prospective cohort study to analyze the effect of cilostazol on the preservation of cognitive function in patients with early-stage cognitive impairment, namely MCI.

Conditions

Mild Cognitive Impairment

Outcome Measures

Primary Outcomes (1)

• Change from baseline in Mini Mental State Examination (MMSE)

  96 weeks

Secondary Outcomes (6)

• Conversion from MCI to All-cause Dementia

  up to 96 weeks

• Cognitive Decline on Clinical dementia rating-sum of boxes (CDR-SB)

  baseline, 48 weeks, and 96 weeks

• Cognitive Decline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) 14

  baseline, 48 weeks, and 96 weeks

• Cognitive Decline on Logical Memory subtest of the Wechsler Memory Scale-Revised (WMS-R)

  baseline, 48 weeks, and 96 weeks

• Functional Decline on Alzheimer's disease Cooperative Study scale for activities of daily living in MCI (ADCS-MCI-ADL)

  baseline, 48 weeks, and 96 weeks

Other Outcomes (2)

• Cognitive Decline on Free and Cued Selective Reminding Test (FCSRT)

  baseline, 48 weeks, and 96 weeks

• Cognitive Decline on Trail making test (TMT)

  baseline, 48 weeks, and 96 weeks

Study Arms (2)

Cilostazol 50mg B.I.D.

EXPERIMENTAL

After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration. Protocol treatment defines as follows; Investigational Treatment: Cilostazol 50mg B.I.D. p.o. 96 Weeks

Drug: Cilostazol

Placebo B.I.D.

PLACEBO COMPARATOR

After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration. Protocol treatment defines as follows; Comparative Treatment: Placebo B.I.D. p.o. 96 Weeks

Drug: Placebo

Interventions

Cilostazol DRUG

Cilostazol 50mg B.I.D.

Placebo DRUG

Placebo B.I.D.

Eligibility Criteria

• Age: 55 Years - 84 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age between 55-84 (inclusive)
• Study partner who sufficiently knows the daily life of the patient
• Patients with MCI who satisfy the core clinical criteria of National Institute for Aging-Alzheimer Association for MCI (nearly equivalent to mild neurocognitive disorder in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) and who also satisfy the following three criteria:
• i) Memory complaint by subject or study partner Type I: Memory complaint by subject that is verified by a study partner Type II: Otherwise, memory complaint by study partner with the evidence of memory impairment Note) Memory complaint by subject that is not verified by study partner will be excluded.
• ii) Mini-Mental State Examination (MMSE) scores between 22 and 28 (inclusive) iii) Clinical Dementia Rating (CDR) = 0.5
• Written informed consent provided for study participation

You may not qualify if:

• Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, epilepsy, multiple sclerosis, cerebral infection, or subsequent complication caused by head trauma.
• Findings of multiple infarction, brain tumor, or subdural hematoma on MRI performed within 48 weeks before provisional registration.
• Contraindications for MRI such as magnetic body or metal.
• History of major depression or bipolar disorder within 48 weeks before provisional registration, alcohol or other substance abuse within 96 weeks before provisional registration, other diseases or unstable conditions.
• Poorly controlled diabetes mellitus (HbA1c\>9.0%).
• Cognitive impairment due to deficiency of vitamin B12 or folate.
• Neurosyphilis.
• Cognitive impairment due to thyroid function abnormality.
• Psychoactive drugs within 4 weeks before provisional registration.
• Oral anticoagulants within 4 weeks before provisional registration.
• Double antiplatelet therapy (cf. Aspirin, Clopidogrel but not Cilostazol) within 4 weeks before provisional registration.
• Poorly controlled diabetes mellitus treated with insulin within 4 weeks before provisional registration.
• Episode of hypoglycemic attack with loss of consciousness within 4 weeks before provisional registration.
• Anti-dementia drugs within 4 weeks before provisional registration.
• Participation in any other new drug study for Alzheimer's disease.

Sponsors & Collaborators

• National Cerebral and Cardiovascular Center, Japan: lead

Study Sites (1)

National Cerebral and Cardiovascular Center

Suita, Osaka, 564-8565, Japan

Location

Related Publications (1)

• Saito S, Suzuki K, Ohtani R, Maki T, Kowa H, Tachibana H, Washida K, Kawabata N, Mizuno T, Kanki R, Sudoh S, Kitaguchi H, Shindo K, Shindo A, Oka N, Yamamoto K, Yasuno F, Kakuta C, Kakuta R, Yamamoto Y, Hattori Y, Takahashi Y, Nakaoku Y, Tonomura S, Oishi N, Aso T, Taguchi A, Kagimura T, Kojima S, Taketsuna M, Tomimoto H, Takahashi R, Fukuyama H, Nagatsuka K, Yamamoto H, Fukushima M, Ihara M; COMCID Trial Investigator Group. Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA Netw Open. 2023 Dec 1;6(12):e2344938. doi: 10.1001/jamanetworkopen.2023.44938.

  PMID: 38048134 DERIVED

MeSH Terms

Conditions

Cognitive Dysfunction

Interventions

Cilostazol

Condition Hierarchy (Ancestors)

Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Tetrazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Quinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Physician (Head of Neurology)

Study Record Dates

• First Submitted: July 1, 2015
• First Posted: July 8, 2015
• Study Start: May 1, 2015
• Primary Completion: August 14, 2020
• Study Completion: December 1, 2020
• Last Updated: December 4, 2020

Record last verified: 2020-12

Locations

JP (1)